**Supplementary Information** 

## Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells

Katherine Margulis,<sup>‡a,b</sup> Alexander Honkala,<sup>‡c</sup> Irina Kalashnikova,<sup>d</sup> Sarah E. Noll,<sup>a</sup> Meghan Hill<sup>d</sup>, Richard N. Zare<sup>\*a</sup> and Bryan R. Smith<sup>\*c,d</sup>

<sup>a</sup> Department of Chemistry, Stanford University, Stanford, CA, 94305, USA

<sup>b</sup> The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112192, Israel

<sup>c</sup> Department of Radiology and the Molecular Imaging Program, Stanford University, Stanford, CA, 94305, USA

<sup>d</sup> Department of Biomedical Engineering, Institute for Quantitative Health Science & Engineering, Michigan State University, East Lansing, MI 48824

<sup>‡</sup> These authors contributed equally

\*Email: zare@stanford.edu; smit2901@msu.edu



**Fig. S1.** Cytotoxicity studies for ICG-loaded NPs. (A) MTT assay. No statistical difference in cytotoxic effects of conjugated and unconjugated NPs on macrophages were detected within the 0.05-100 ng/ml concentration range by T-test. (B) Proliferation assay. Negative control with cycloheximide showed decreased proliferation; (C) Live/dead cell analysis by flow cytometry. Cell viability was compared to untreated cells (in PBS) and heat-treated cells.

For the methods used in these studies, please see the main text Experimental/ Toxicity tests.



Figure S2: Gating Strategy for Figure 5 Data.



Figure S3. Gating Strategy for Figure 6 Data.